Led by Director and Principal Andrew Briggs, DPhil, and CEO John Schneider, PhD, AHE researchers and consultants have extensive knowledge and experience in the field of health economics and outcomes research (HEOR). These services include a wide variety of offerings across the product development continuum. In the early stages of development, we provide insights and analysis on potential market size and the design of rigorous economic evaluations, such as clinical studies and cost-effectiveness analysis. In later stages of development, we can offer more in-depth analyses to support expanded market access. For more information, view one of our past presentations on Establishing the Value of New Drugs, Devices, and Diagnostics.
Health Economics and Outcomes Research (HEOR)
Health Economics and Outcomes Research (HEOR)
Focus: HEOR Analytics
Traditional HEOR has focused mainly on model building, utility development, and so on. But as data sources have become more nuanced and complex, and product value pathways have become more intricate, there is a need to push the limits of HEOR by applying state-of-the art statistical analyses of data. To address this need, Avalon has developed a practice area within its HEOR capability called HEOR Analytics. These tasks include novel statistical analyses of HEOR data, such as trial data or quality of life data, and novel applications of those analyses to statistical and economic models.
We have extensive experience in advising health care leaders and managers in the following HEOR areas:
- Evidence Planning & Study Design
- Conceptual Models
- Literature Synthesis & Meta-Analysis
- Data Sourcing, Analysis & Interpretation
- Economic Modeling, Cost Effectiveness Analysis & Budget Impact Analysis
- Web-Based Graphical Model User Interfaces
- Patient-Reported Outcomes & Utilities*
- Market Access & Reimbursement
- Payer & Purchaser Engagement
- Peer-Reviewed Publications & Communications
- Medical device total cost of ownership (TCO) analysis
- Real-world data analysis using large datasets, including Truven, Pharmetrics, Medicare claims data, etc.
- Support to Value Analysis Teams (VAT) & Value Analysis Committees (VACs) for hospitals & health systems**
- Hospital Value Analysis (HVA) of medical devices**
- Clinical research monitoring and study coordination
- Predictive Analytics & Forecasting**
- Market Research**
- Market Development & Expansion**
- Investor Research & Analysis**
- Benchmarking Reimbursement & Performance Metrics**
* Provided through a collaborative partnership with Acaster-Lloyd Consulting.
**For European markets, also provided through our collaborative partnership with Oberender.
Recent Publications
A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet. 2018
Enhancing the value of the ASCO value framework. 2018
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. 2018
High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study. 2018
EQ-5D-5L: Smaller steps but a major step change? 2018.
Health impacts of the WIAT programme to improve local woodlands for deprived urban communities : a quasi-experimental study. 2018
Estimating the Long-Term Outcomes Associated With ImmunoOncology Therapies: Challenges and Approaches for Overall Survival Extrapolations. 2018
Follow Us
Contact
© 2018 Avalon Health Economics. All rights reserved.